Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Name: Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Author: Chung, Hyun Cheol

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. — المؤلف: Chung, Hyun Cheol — Journal for immunotherapy of cancer 20200331

المؤلف: Chung, Hyun Cheol
النشر: Journal for immunotherapy of cancer 20200331
الوصف: 30 p.
الموضوعات: Aged؛ Antibodies, Monoclonal؛ Antibodies, Monoclonal, Humanized؛ Antineoplastic Agents, Immunological؛ B7-H1 Antigen؛ Esophageal Neoplasms؛ Esophagogastric Junction؛ Female